{
  "docId": "019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "docSlug": "1af2d4156bf2490b3ac2801b5487abdf",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 44 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 44,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide establishes a baseline for FXN levels in healthy individuals to contextualize the deficiency seen in Friedreich's Ataxia (FA) patients.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4f8b-70c9-adf8-0b3abb8c1303/13",
  "deckHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "deckJsonHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303.json",
  "deckAnchorHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.35,
        "x": 0.084,
        "y": 0.288
      },
      "kind": "chart",
      "text": "Median Frataxin Concentration (pg/µg) in Homozygous Healthy Volunteers (n = 60)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03b8dadb-46e9-4fa5-a8f5-2b0ff45ba3d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.44,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "list",
      "text": "Patients with FA only produce ~20-40% of normal frataxin levels depending on the tissue, sampling technique, and assay considered. Lower FXN levels seen with typical onset (5 to 15 years of age). Higher FXN levels seen with late onset (after 25 years of age).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77b932e6-5f5a-4ed1-bdba-a8e1a14f8c27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.032,
        "w": 0.864,
        "x": 0.036,
        "y": 0.155
      },
      "kind": "paragraph",
      "text": "Recently completed non-interventional study measured FXN in homozygous healthy volunteers",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a55988c3-7549-4fd1-953e-3d69fe487f4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.145,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "FXN concentrations were measured in skin and buccal cells from 60 homozygous healthy volunteers utilizing the same sampling technique and assay as clinical trials of nomlabofusp; FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations normalized to total cellular protein content in each sample. 1. E.C. Deutsch et al. Molecular Genetics and Metabolism 101 (2010) 238–245. 2. Friedreich’s Ataxia Research Alliance",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79dd6315-5b64-4be6-a462-1346f576c22b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.928,
        "x": 0.036,
        "y": 0.075
      },
      "kind": "title",
      "text": "CLIN-1601-002: Top-line Non-interventional Study Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "874f43d8-d80c-4a4d-97f7-c7a80378aa5d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 44,
      "from": 4,
      "beatId": "800ed350-717e-4cf5-a054-3d6626879633",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Multiple pages showcase clinical trial progress and data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}